Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Novel Therapeutic Trends in Pneumonia: Antibiotics and Mesenchymal Stem Cells

Version 1 : Received: 31 March 2021 / Approved: 1 April 2021 / Online: 1 April 2021 (16:18:25 CEST)

How to cite: Ly, J.; Chu, Q.; Zhong, L. Novel Therapeutic Trends in Pneumonia: Antibiotics and Mesenchymal Stem Cells. Preprints 2021, 2021040031 (doi: 10.20944/preprints202104.0031.v1). Ly, J.; Chu, Q.; Zhong, L. Novel Therapeutic Trends in Pneumonia: Antibiotics and Mesenchymal Stem Cells. Preprints 2021, 2021040031 (doi: 10.20944/preprints202104.0031.v1).

Abstract

Pneumonia remains a major cause of morbidity and mortality worldwide, especially during COVID-19 pandemic. With the significant global health burden that pneumonia poses, it is es-sential to improve therapeutic and management strategies. The increasing emergence of antibiotic resistant bacterial strains limits options for effective antibiotic use. New antibiotics for treatment of pneumonia may address deficits in current antimicrobial drugs, with an ability to cover both typical, atypical, and resistance pathogen. Several of these newer drugs also have structural characteristics that allow for a decreased propensity in development of bacterial resistance. Po-tential use of stem cell therapies in place of corticosteroid treatments may also offer an im-provement in patient outcomes. Human mesenchymal stem cell treatments have shown efficacy and safety in treating COVID-19 induced pneumonia. Combined treatment with both stem cells and antibiotics in pneumonia in a rabbit model has also shown significantly increased efficacy in comparison to antibiotic treatment alone, presenting yet another possible route for a novel strategy in treating pneumonia, though additional future studies are necessary before clinical implementation. While pneumonia remains a major disease of concern, having newer approved antibiotics as well as novel therapies such as stem cell treatments in the pipeline offers clinicians more options in effectively treating pneumonia.

Keywords

Community-Acquired Pneumonia; Hospital-Acquired Pneumonia; COVID-19; Antibiotics; Mes-enchymal Stem Cells; Corticosteroids

Subject

MEDICINE & PHARMACOLOGY, Allergology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.